United States - English - NLM (National Library of Medicine)

astellas pharma us, inc. - isavuconazonium sulfate (unii: 31q44514jv) (isavuconazole - unii:60uto373ke) - isavuconazonium sulfate 186 mg - cresemba® is indicated for the treatment of invasive aspergillosis as follows: cresemba for injection : adults and pediatric patients 1   year of age and older [see clinical studies ( 14.1 ) and clinical pharmacology ( 12.4 )] cresemba capsules : adults and pediatric patients 6 years of age and older who weigh 16 kilograms ( kg ) and greater [see dosage and administration ( 2.3 ) clinical studies ( 14.1 ) and clinical pharmacology ( 12.4 )] cresemba is indicated for the   treatment of invasive mucormycosis as follows: cresemba for injection : adults and pediatric patients 1   year of age and older [see clinical studies ( 14.1 ) and clinical pharmacology ( 12.3 , 12.4 )] cresemba capsules : adults and pediatric patients 6 years of age and older who weigh 16 kg and greater [see dosage and administration ( 2.3 )], clinical studies ( 14.1 ) and clinical pharmacology ( 12.3 ,   12.4 )] specimens for fungal culture and other relevant laboratory studies (including histopathology) to isolate and identify causative organism(s) should be obtained prior to initiating antifungal therapy. therapy may be instituted before the results of the cultures and other laboratory studies are known. however, once these results become available, antifungal therapy should be adjusted accordingly. risk summary based on findings from animal studies, cresemba may cause fetal harm when administered to a pregnant woman. there are no available human data on the use of cresemba in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal reproduction studies, perinatal mortality was increased in the offspring of pregnant rats dosed orally with isavuconazonium sulfate at approximately 0.5 times the clinical exposure during pregnancy through the weaning period. in animal studies when isavuconazonium chloride was administered by oral gavage to pregnant rats and rabbits during organogenesis at exposures corresponding to less than the human maintenance dose, increases in the incidences of multiple skeletal abnormalities, including rudimentary cervical ribs and fused zygomatic arches, were observed (see data). advise pregnant women of the potential risk to a fetus [see warnings and precautions (5.4)] . the estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. data animal data isavuconazonium chloride administration during organogenesis (gestational days 6-17 in rats and gestational days 6-18 in rabbits) was associated with dose-related increases in the incidences of rudimentary cervical ribs in rats and rabbits at 30 and 45 mg/kg, respectively, equivalent to about 0.2 and 0.1 times of the clinical exposure based on auc comparisons. in rats, dose-related increases in the incidences of zygomatic arch fusion and supernumerary ribs/rudimentary supernumerary ribs were also noted at 30 mg/kg and above, equivalent to 0.2 times the human auc. skeletal abnormalities have also been observed in embryo-fetal development studies of other azole antifungal agents. isavuconazonium sulfate increased perinatal mortality in the pups when orally administered to pregnant rats during pregnancy and lactation (gestational day 6 through postpartum day 20) at doses up to 90 mg/kg/day (approximately 0.5 times the clinical exposure based on auc comparison). no effect on the duration of pregnancy or delivery was seen in the pups at this same dose. risk summary there are no data on the presence of isavuconazole in human milk, the effects on the breastfed infant or the effects on milk production. isavuconazole was present in the milk of lactating rats following intravenous administration. when a drug is present in animal milk, it is likely that the drug will be present in human milk. therefore, breastfeeding should be discontinued during treatment with cresemba. contraception cresemba may cause embryo-fetal harm when administered to pregnant women [see warnings and precautions (5.4) and use in specific populations (8.1)]. advise female patients of reproductive potential to use effective contraception during treatment with cresemba and for 28 days after the final dose. invasive aspergillosis the safety and effectiveness of cresemba for injection for the treatment of invasive aspergillosis have been established in pediatric patients 1 year of age and older. the safety and effectiveness of cresemba capsules for the treatment of invasive aspergillosis have been established in pediatric patients 6 year of age and older weighing 16 kg and greater. use of cresemba in this age group for treatment of invasive aspergillosis is supported by evidence from one adequate and well-controlled trial in adult patients and additional pharmacokinetic and safety data in pediatric patients 1 year of age and older [see clinical pharmacology (12.3)]. adverse reactions in this pediatric population were similar to those reported in the adult population [see adverse reactions (6.1)]. the safety and effectiveness of cresemba capsules for treatment of invasive aspergillosis have not been established in pediatric patients younger than 6 years of age or who weigh less than 16 kg because the oral route of administration was not assessed in this pediatric patient age cohort. the safety and effectiveness of cresemba for treatment of invasive aspergillosis in pediatric patients less than 1 year of age have not been established. invasive mucormycosis the safety and effectiveness of cresemba for injection for the treatment of invasive mucormycosis have been established in pediatric patients 1 year of age and older. the safety and effectiveness of cresemba capsules for the treatment of invasive mucormycosis have been established in pediatric patients 6 year of age and older weighing 16 kg and greater. use of cresemba in this age group for treatment of invasive mucormycosis is supported by one open-label trial in adult patients with invasive mucormycosis, a retrospective review of survival data for adult patients with untreated invasive mucormycosis, and additional pharmacokinetic and safety data in pediatric patients 1 year of age and older [see clinical pharmacology (12.3 )]. adverse reactions in this pediatric population were similar to those reported in the adult population [see adverse reaction s (6.1)]. the safety and effectiveness of cresemba capsules for treatment of invasive mucormycosis have not been established in pediatric patients younger than 6 years of age who weigh less than 16 kg because the oral route of administration was not assessed in this pediatric patient age cohort. the safety and effectiveness of cresemba for treatment of invasive mucormycosis in pediatric patients less than 1 year of age have not been established. of the 547 patients who received cresemba in the phase 2 and 3 trials, 86 (16%) of patients were greater than 65 years of age and 20 (4%) were greater than 75 years of age. the pharmacokinetics of isavuconazole are comparable in young and elderly subjects (65 years of age and older) [see clinical pharmacology (12.3)] . no dose adjustment of cresemba is needed in elderly patients. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. of the 403 patients who received cresemba in the phase 3 trials, 79 (20%) of patients had an estimated glomerular filtration rate (gfr) less than 60 ml/min/1.73 m2 . no dose adjustment is needed in patients with mild, moderate, or severe renal impairment, including those patients with end-stage renal disease (esrd) [see clinical pharmacology (12.3)] . no dose adjustment is necessary in patients with mild or moderate hepatic impairment (child-pugh class a and b) [see clinical pharmacology (12.3)] . cresemba has not been studied in patients with severe hepatic impairment (child-pugh class c) and should be used in these patients only when the benefits outweigh the risks. clinical monitoring for cresemba-related adverse reactions is recommended when treating patients with severe hepatic impairment [see warnings and precautions (5.1)] .

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - desferrioxamine mesilate - powder for solution for injection - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - desferrioxamine mesilate - powder for solution for injection - 2gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - amphotericin b phospholipid complex - suspension for infusion - 5mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - isavuconazonium sulfate - powder for solution for infusion - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - isavuconazonium sulfate - capsule - 100mg

United States - English - NLM (National Library of Medicine)

jubilant hollisterstier llc - yeast (unii: 3ny3sm6b8u) (yeast - unii:3ny3sm6b8u) - equus caballus hair 0.01 g in 1 ml - non-standardized allergenic extracts are indicated for: - skin test diagnosis of individuals with a clinical history of allergy to the specific corresponding allergens. non-standardized allergenic extracts are indicated for: - immunotherapy for the reduction of allergen-induced allergic symptoms confirmed by positive skin test or by in vitro testing for allergen specific ige antibodies for the specific corresponding allergens. non-standardized allergenic extracts are contraindicated in individuals with the following conditions: - severe, unstable or uncontrolled asthma. - history of any severe systemic reaction to the allergen extract when administered for diagnosis or treatment. - medical conditions that reduce the ability to survive anaphylaxis. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes.  in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respecti

Ireland - English - HPRA (Health Products Regulatory Authority)

gilead sciences ireland uc - amphotericin b - concentrate for solution for infusion - 50 milligram(s) - antibiotics; amphotericin b

United States - English - NLM (National Library of Medicine)

guna spa - aspergillus niger var. niger (unii: 9ioa40ang6) (aspergillus niger var. niger - unii:9ioa40ang6), candida albicans (unii: 4d7g21hdbc) (candida albicans - unii:4d7g21hdbc), malic acid (unii: 817l1n4ckp) (malic acid - unii:817l1n4ckp), centella asiatica (unii: 7m867g6t1u) (centella asiatica - unii:7m867g6t1u), mercuric chloride (unii: 53gh7mzt1r) (mercuric cation - unii:ed30fj8y42), rhizopus stolonifer (unii: fee198dk4q) (rhizopus stolonifer - unii:fee198dk4q), sodium diethyl oxalacetate (unii: 6ca025y4 - aspergillus niger    12x, 30x, 200x    detoxification candida albicans    12x, 30x, 200x    detoxification dl-malic acid        6x,12x, 30x    cell metabolism hydrocotyle asiatica    6x    cell metabolism mercurius corrosivus    6x    cell metabolism mucor mucedo        12x, 30x, 200x    detoxification natrum oxalaceticum    6x,12x, 30x    cell metabolism pink trumpet tree    4x    detoxification sulphur            6x    detoxification temporary relief of symptoms related to fungal yeast overgrowth in skin and mucosa, such as: - skin rashes - redness, itching - intestinal gas and bloating take 15 minutes before meals.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - isavucozanium sulfate -